Ras Inhibitors Targeting Switch 2 Pocket for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for Ras proteins, particularly oncogenic mutants like K-RasG12C, which are commonly associated with various cancers, leading to uncontrolled cell proliferation and survival.
Innovation Solution
Development of novel compounds that target specific amino acid residues of Ras proteins, such as K-Ras, N-Ras, and H-Ras, by binding to the Switch 2 binding pocket, thereby modulating their activity and inhibiting their oncogenic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used, then general cancer therapy is provided, but effective inhibition of Ras protein activity is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the Switch 2 binding pocket of mutant Ras proteins. The compounds contain electrophilic moieties that covalently modify cysteine residues (such as Cys12 in K-RasG12C) within this specific local region, thereby selectively inhibiting mutant Ras activity while preserving normal Ras signaling pathways. This localized targeting approach resolves the contradiction by providing effective cancer treatment through selective inhibition without broadly affecting all cellular processes.
Solution Approach 2:
The patent employs an intermediary mechanism where the compounds act as mediators between the therapeutic goal and the Ras protein target. The electrophilic moieties serve as chemical intermediaries that form covalent bonds with specific cysteine residues in the Switch 2 region, thereby translating the design intent into effective Ras inhibition. This intermediary approach enables reliable cancer treatment by creating a direct chemical connection to the target protein's critical functional region.
2Object-affected harmful factors
If Ras protein activity is inhibited, then oncogenic effects are blocked, but normal Ras signaling may be affected
Solution Approach 1:
The patent achieves selectivity through local quality modifications in the Switch 2 binding pocket. Mutant Ras proteins exhibit altered local properties in this region, such as exposed cysteine residues (e.g., Cys12 in K-RasG12C) that are not present or are less accessible in normal Ras. The compounds exploit these local structural differences to selectively bind and inhibit mutant forms while leaving normal Ras signaling intact, thereby resolving the adaptability challenge.
Solution Approach 2:
The patent uses a copying strategy by designing compounds that replicate the binding characteristics of natural effectors but with enhanced specificity for mutant Ras. The electrophilic moieties copy the functional role of natural binding partners while introducing mutant-specific recognition elements, allowing selective inhibition of oncogenic Ras without affecting normal physiological signaling pathways.
3Reliability
If compounds bind to Switch 2 binding pocket, then nucleotide exchange is disrupted, but compound design complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound into distinct functional modules: a core structure that targets the Switch 2 binding pocket and separate electrophilic moieties that provide covalent binding capability. This modular segmentation allows for systematic optimization of each component's function while managing overall molecular complexity, enabling reliable disruption of nucleotide exchange without excessive structural complexity.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying key molecular parameters such as the electrophilic moiety type, its position relative to the core structure, and its reactivity. By adjusting these parameters, the compounds achieve optimal balance between binding affinity, selectivity, and controlled reactivity toward cysteine residues in the Switch 2 region, thereby effectively disrupting nucleotide exchange while maintaining manageable compound complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit Ras protein activity, disrupting GEF-catalyzed nucleotide exchange and blocking effector binding, demonstrating potential as therapeutic agents for cancer treatment by targeting specific mutations without affecting normal Ras signaling.
Implementation Method 1
capable of binding an amino acid residue of a Ras protein
Data Source
AI summary
Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.